Bicara Therapeutics Inc. (BCAX) Stock Forecast & Price Target

Compare

71 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BCAX Analyst Ratings

Strong Buy

7 Buy

2 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Bicara

Therapeutics Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BCAX Stock 12 Month Forecast

Average Price Target

$30.75

▲(74.32% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Bicara Therapeutics Inc. in the last 3 months. The average price target is $30.75 with a high forecast of $48.00 and a low forecast of $11.00. The average price target represents a 74.32% change from the last price of $17.64.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","49":"$49","18.25":"$18.25","28.5":"$28.5","38.75":"$38.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18.25,28.5,38.75,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.33,19.689230769230768,22.048461538461538,24.407692307692308,26.766923076923078,29.126153846153848,31.485384615384614,33.84461538461538,36.20384615384616,38.56307692307692,40.9223076923077,43.28153846153846,45.64076923076923,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.33,18.36230769230769,19.394615384615385,20.426923076923075,21.459230769230768,22.49153846153846,23.52384615384615,24.556153846153844,25.588461538461537,26.62076923076923,27.653076923076924,28.685384615384613,29.717692307692307,{"y":30.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.33,16.84307692307692,16.356153846153845,15.869230769230768,15.382307692307691,14.895384615384614,14.408461538461538,13.92153846153846,13.434615384615384,12.947692307692307,12.46076923076923,11.973846153846154,11.486923076923077,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$48.00

Average Price Target$30.75

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Catanzaro

Mizuho Securities

$18

Hold

2.04%

Upside

Initiated

12/18/25

Bicara Therapeutics initiated with a Neutral at MizuhoBicara Therapeutics initiated with a Neutral at Mizuho

Kelsey Goodwin

Piper Sandler

$36

Buy

104.08%

Upside

Reiterated

12/08/25

Piper Sandler Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Stephen Willey

Stifel Nicolaus

$48

Buy

172.11%

Upside

Reiterated

12/08/25

Stifel Nicolaus Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)

Robert Burns

H.C. Wainwright

$40

Buy

126.76%

Upside

Reiterated

12/08/25

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation

Soumit Roy

JonesTrading

$27

Buy

53.06%

Upside

Reiterated

12/08/25

Promising Efficacy and Investment Potential for Bicara Therapeutics' FICERA in Combination with Keytruda

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$30

Buy

70.07%

Upside

Reiterated

12/08/25

Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Judah Frommer

Morgan Stanley

$36

Buy

104.08%

Upside

Reiterated

12/07/25

Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics' Buy Rating

Eva Fortea Verdejo

Wells Fargo

$8→$11

Hold

-37.64%

Downside

Reiterated

11/11/25

Wells Fargo Sticks to Its Hold Rating for Bicara Therapeutics Inc. (BCAX)

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/10/25

Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Editas Medicine (EDIT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Catanzaro

Mizuho Securities

$18

Hold

2.04%

Upside

Initiated

12/18/25

Bicara Therapeutics initiated with a Neutral at MizuhoBicara Therapeutics initiated with a Neutral at Mizuho

Kelsey Goodwin

Piper Sandler

$36

Buy

104.08%

Upside

Reiterated

12/08/25

Piper Sandler Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Stephen Willey

Stifel Nicolaus

$48

Buy

172.11%

Upside

Reiterated

12/08/25

Stifel Nicolaus Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)

Robert Burns

H.C. Wainwright

$40

Buy

126.76%

Upside

Reiterated

12/08/25

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation

Soumit Roy

JonesTrading

$27

Buy

53.06%

Upside

Reiterated

12/08/25

Promising Efficacy and Investment Potential for Bicara Therapeutics' FICERA in Combination with Keytruda

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$30

Buy

70.07%

Upside

Reiterated

12/08/25

Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Judah Frommer

Morgan Stanley

$36

Buy

104.08%

Upside

Reiterated

12/07/25

Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics' Buy Rating

Eva Fortea Verdejo

Wells Fargo

$8→$11

Hold

-37.64%

Downside

Reiterated

11/11/25

Wells Fargo Sticks to Its Hold Rating for Bicara Therapeutics Inc. (BCAX)

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/10/25

Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Editas Medicine (EDIT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bicara Therapeutics Inc.

1 Month

xxx

Success Rate

9/12 ratings generated profit

Average Return

+3.31%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +3.31% per trade.

3 Months

xxx

Success Rate

6/10 ratings generated profit

Average Return

+13.07%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +13.07% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

7/8 ratings generated profit

Average Return

+32.19%

reiterated a buy rating last month

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +32.19% per trade.

2 Years

xxx

Success Rate

7/8 ratings generated profit

Average Return

+34.30%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +34.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCAX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BCAX has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BCAX average Analyst price target in the past 3 months is 30.75.

Each month's total comprises the sum of three months' worth of ratings.

BCAX Financial Forecast

BCAX Earnings Forecast

Next quarter’s earnings estimate for BCAX is -$0.69 with a range of -$0.76 to -$0.57. The previous quarter’s EPS was -$0.67. BCAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BCAX has Performed in-line its overall industry.

No data currently available

BCAX Sales Forecast

Next quarter’s sales forecast for BCAX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BCAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BCAX has Performed in-line its overall industry.

BCAX Stock Forecast FAQ

What is BCAX’s average 12-month price target, according to analysts?

Based on analyst ratings, Bicara Therapeutics Inc.’s 12-month average price target is 30.75.

What is BCAX’s upside potential, based on the analysts’ average price target?

Bicara Therapeutics Inc. has 74.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BCAX a Buy, Sell or Hold?

Bicara Therapeutics Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.

What is Bicara Therapeutics Inc.’s price target?

The average price target for Bicara Therapeutics Inc. is 30.75. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $11.00. The average price target represents 74.32% Increase from the current price of $17.64.

What do analysts say about Bicara Therapeutics Inc.?

Bicara Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of BCAX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Bicara Therapeutics Inc. (BCAX) Stock Forecast & Price Target

BCAX Analyst Ratings

BCAX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bicara Therapeutics Inc.

BCAX Analyst Recommendation Trends

BCAX Financial Forecast

BCAX Earnings Forecast

BCAX Sales Forecast

BCAX Stock Forecast FAQ

Detailed List of Analyst Forecasts